Moonshot Client Axolotl Announces Merger with Carmell Therapeutics; Axolotl's Shareholders To Receive $65M In CTCX Stock Upon Closing; Gain Up To $75M In Potential Milestone Equity Payments
Portfolio Pulse from Benzinga Newsdesk
Axolotl, a client of Moonshot, has announced a merger with Carmell Therapeutics. Upon closing, Axolotl's shareholders will receive $65M in CTCX stock and could gain up to $65M in potential milestone equity payments.
September 12, 2023 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Carmell Therapeutics' stock (CTCX) may see increased demand as Axolotl's shareholders are set to receive $65M in CTCX stock upon the merger's closing.
The merger announcement between Axolotl and Carmell Therapeutics will result in Axolotl's shareholders receiving $65M in CTCX stock. This could increase demand for CTCX shares, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100